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Critical Evaluation of LindaneÕs Breast Cancer Risk
by Renu Gandhi, Serge-Alain Wandji, and Suzanne Snedeker
AuthorÕs Note: The reader is encouraged to read the attached document, Appendix B, which includes an explanation of the BCERF
Breast Carcinogen Classification System, before reading this Critical Evaluation.
I. Chemical Information
A. Common Names: Lindane (except in the United Kingdom),
gamma HCH, gamma 1-1 BHC (Worthing and Hance, 1991)
B. Chemical Name: gamma isomer of 1a, 2 a , 3b, 4 a , 5 a ,
6b-Hexachlorocyclohexane (IUPAC) (Worthing and Hance,
1991)
C. Chemical Formula: C6H6Cl6  (Montgomery, 1993)
D. FormulatorsÕ Trade Names: AcitoxÒ (Agro Chemicals
Industries Ltd.); HammerÒ (Agsin Pte. Ltd.); EtanÒ (Diachem
S.P.A.); Wireworm FSÒ (DowElanco Ltd.); LindasunÒ (Gupta
Chemicals Pvt. Ltd.); GermateÒ Plus, Lindane 30, Lindane
40% (Gustafson, Inc.); Gamma-Mean 400Ò, Gamma-Mean L.O.
Ò, Gamma Mean SeedÒ, Gamma-UpÒ, (Oregon-California
Chemicals, Inc.); KwellÒ (Reed and Carnrick), SulbenzÒ
(Sulphur Mills, Ltd.); QuelladaÒ (Stafford-Miller Ltd);
LindagamÒ, NovigamÒ, SilvanolÒ (Meister, 1997).
E. Discontinued Trade Names: IsotoxÒ (Chevron Chemical
Co.); Chimac L200Ò, LidaxÒ (Chimac-Agriphar S. A.); AgroxÒ
S (+ captan), AgroxÒ 3-Way (+ captan + diazinon) (Chipman
Chemicals); GammexaneÒ, GammasanÒ, GammalinÒ 20,
DidigamÒ (+DDT) (ICI Agrochemicals); Noita-koisumuÒ (+
DDT) (Kemira Oy); Lacco Hi LinÒ, Lacco Lin-O-MulsionÒ and
Lin-O-SolÒ (Los Angeles Chemical Co.); Cloroble FortÒ (+
copper oxide + endosulfan) (Pechiney Progil); LindolÒ (Rhone-
Poulenc); KotolÒ, LindacolÒ, (Shell Chemicals, UK Ltd.);
AgronexitÒ, InexitÒ, NexitÒ (Shell International Chemical Co.
Ltd.); CeregramÒ (+methoxyethylmercury silicate), SopragamÒ
(+ parathion) (SOPRA) (Meister, 1997).
F. CAS Registry Number: 58-89-9 (Montgomery, 1993)
G. Chemical Structure:  hexachlorocyclohexane
Cl Cl
     Cl          Cl
Cl  Cl
II. History of Use, Usage and Nomenclature:
A. History of Use:
Hexachlorocyclohexane (HCH) was first prepared by Michael
Faraday in 1825 by adding chlorine to benzene in sunlight
(IARC, 1979). It was used as a smoke bomb during World War
I. Its insecticidal properties were described independently by
Dupire and Raucourt in 1943 (Smith, 1991). Technical-grade
HCH is a mixture of 65 to 70% alpha-HCH, 7 to 10% beta-
HCH, 14 to 15% gamma-HCH and 10% of other isomers and
compounds (IPCS, 1991). The pure gamma-HCH (g-HCH)
isomer is called lindane, but may also be referred to as gamma-
benzene hexachloride (g-BHC). In this document, lindane is
used to denote the purified gamma-isomer of HCH and
technical-grade HCH is used to denote the mixture of HCH
isomers. HCH is used when all isomers of
hexachlorocyclohexane are present, but the proportions of the
different isomers was not defined.
Slade showed in 1945, that the insecticidal properties of
technical-grade HCH were due to the gamma-isomer, or pure
lindane (Smith, 1991). Lindane is a contact poison since it is
absorbed directly into the parasite and its eggs, as well as a
stomach poison with some fumigant action (PDR, 1998;
Worthing and Hance, 1991). Lindane is effective against a broad
range of insects including cutworms and wireworms that eat
leaves, insects that live in the soil, human and animal parasites
such as fleas, ticks, lice and scabies, and in the treatment of
mange (USEPA, 1990).
Commercial production of lindane in the U.S. was first reported
in 1950 (IARC, 1979). Lindane was used as a spray for foliage,
in soil applications, for seed treatment, and in baits for rodent
control (Worthing and Hance, 1991). Registrations for lindane
included its use as an insecticide for the treatment of a variety of
fruits, seed grains and vegetable crops (including greenhouse
vegetables and tobacco), in forestry (including Christmas tree
treatment), for poultry and livestock, on animal farms and
cultivated land, for household and treatment of uncultivated land
(ATSDR, 1994; IARC, 1979). The major non-agricultural use
for lindane has been for wood and timber protection (IPCS,
1991). In human medicine, lindane is still used at 1% levels for
treatments of head lice, usually as lotions, creams, and
shampoos (IARC, 1979; Smith, 1991; PDR, 1998).
B. Nomenclature: There is extensive literature on technical-
grade lindane and the alpha- and beta-HCH isomers.
Discussions in this evaluation focus on lindane, the gamma-
HCH isomer. A recent study reports no significant
interconversion of lindane into other isomers of HCH during its
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metabolism (Waliszewski, 1993). An earlier study indicated the
presence of small amounts of hexachlorobenzene (HCB) as a
metabolite of lindane (Smith, 1991), but no conversion of
lindane to hexachlorobenzene was detected in several other
studies on lindane metabolism (IPCS, 1991).
C. Usage:
1. Agricultural Use:
The amount of active ingredient lindane used for fruits and
vegetable cultivation per year during 1990-1993, was estimated
at 61,189 lbs (Gianessi and Anderson, 1995). It ranked 51st in
insecticide usage on agricultural crops, and was among the ten
least used insecticides in the U.S. during this period (Gianessi
and Anderson, 1995). Estimates of its use in New York State
were not available.
2. Non-Cropland Use:
Less than 1000 kg of lindane was used in the U.S. in human
medicine in 1971 (IARC, 1979). More recent estimates of its
use were not found.
III. Current Regulatory Status:
A. Regulatory Status:
Concern over carcinogenicity, delayed toxic effects and acute
toxicity risks related to hazards in aquatic wildlife, prompted
EPA to issue a notice of Rebuttable Presumption Against
Registration (RPAR), and continued registration of pesticide
products containing lindane in 1977 (IARC, 1979). RPAR was
the term used for the Special Review Process prior to 1986
(USEPA, 1996b). [Note: ÒThe Special Review processÓ is set
in motion when EPA has reason to believe that the use of a
pesticide may result in adverse effects to people or the
environmentÓ (USEPA, 1996b)]. Following the initiation of
RPAR, use of HCH isomers other than the gamma-isomer was
voluntarily canceled. In October 1983, a notice of intent to
cancel pesticide products containing lindane was issued by EPA
(USEPA, 1990), but it was successfully challenged by
registrants. In 1985, lindane was classified as a Restricted Use
Pesticide, to be applied only by a certified applicator using
protective equipment (USEPA, 1990). Its use for aquatic
application and in vaporizers was canceled. New regulations
were issued requiring specific warning statements on the labels
of all lindane products. The use of existing stocks of lindane
products by end users is permitted until the supply is
exhausted. Any existing stock of products within the possession
of the registrant, distributors or retailers must be disposed of in
accordance with the Resource Conservation and Recovery Act
(USEPA, 1990). EPA requires that spills or accidental
discharges into the environment of 1 lb or more must be
reported.
B. Drinking Water Standards and Health Advisories:
1. Maximum Contaminant Level:
The EPA has set the Maximum Contaminant Level (MCL) in
drinking water for lindane at 0.0002 mg/L (USEPA, 1996a).
This is an enforceable limit on the maximum allowable
concentration in public water supplies.
2. Health Advisory:
Health advisory (HA) levels for drinking water as are follows
(USEPA, 1996a):
10 kg child
· One day = 1 mg/L
· Ten day = 1 mg/L
70 kg adult
· Long term = 0.1 mg/L
· Lifetime = 0.0002 mg/L
The HA are non-enforceable limits of the concentration of the
chemical in the drinking water that is not expected to cause any
adverse noncarcinogenic health effects when consumed for no
more than the time period specified, with a margin of safety
(USEPA, 1996a).
C. Workplace Regulations:
The Occupational Safety and Health Commission (OSHA) has
set the maximum allowable level in workplace air at 0.5 mg/m3
for 8 hours per day and 40 hours per workweek. This is also the
exposure limit recommended by the National Institute of
Occupational Health and Safety (NIOSH) (NTIS, 1994).
D. Food Tolerances:
The amount of pesticide permitted to occur on the edible
portion of raw agricultural commodities and in processed foods,
called tolerances, are set by EPA. Residue tolerances for lindane
are: 0.1 mg/kg for pecans, 1 mg/kg for fruits and vegetables, 3
mg/kg for squashes, lettuce, melons and mushrooms, 4 mg/kg
for pork and 7 mg/kg for other meat-fat (USEPA, 1998).
IV. Summary of Evidence of Overall
Carcinogenicity
A. Human Studies
1. Case Reports:
Case reports alone are inadequate to infer a causal relationship
for carcinogenicity of chemicals. They may indicate a need for
further studies of a chemical and associated health risks in larger
case-control studies.
Three case reports have linked lindane exposures with leukemia.
A 66 year old male patient diagnosed with acute myeloblastic
leukemia had used aerosol mixtures containing lindane,
piperonyl butoxide and pyrethrum in different organic solvents
(kerosene, xylene and toluene) (Sidi et al., 1983). Another case-
report describes two cousins, both male, with no family history
of cancer who were diagnosed with paramyeloblastic leukemia
after occupational exposure to Gammexane¨, a lindane
containing insecticide (Jedlicka et al., 1958). Exposure to a
lindane and toxaphene mixture was implicated in a case of
myelomonocytic leukemia, secondary to aplastic anemia (IARC,
1979). These are reports of rare incidences of leukemia among
people who were exposed to many chemicals including lindane.
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While providing insufficient evidence of a causal relationship,
they do suggest the need for evaluating the incidence of
leukemia among populations exposed to lindane.
2. Population-Based Case-Control Studies
Pesticide use was evaluated in the families of 45 children who
were diagnosed with brain cancer (Missouri Cancer Registry) by
the age of ten years. Among the families that participated in the
study, 97.8% recalled having used pesticides between when the
child was of seven months of age and the diagnosis of cancer
(Davis et al., 1992). A significant association was observed
between the use of a lindane containing treatment against head
lice, KwellÒ (1% lindane) and the odds ratio (OR) for childhood
brain cancer (OR = 4.6; 95% CI 1.0-21.3; p values not stated)
in comparison with 85 cancer-free friends of the same age and
sex as controls (Davis et al., 1993). Comparison with a control
group of 108 other childhood cancers revealed a modest but not
significant increase in the risk for brain cancer (OR = 1.9; 95%
CI 0.6-6.9; p values not stated). The small sample size, lack of
detailed exposure verification, potential for recall bias, and of
multiple product use are limiting factors of this study. However,
since anti-lice treatments are frequently used on children, this
observation warrants further investigation.
In another case-control study of 266 cases and 547 controls
among male farmers in Iowa and Minnesota, the risk for non-
HodgkinÕs lymphoma (NHL) in those who had ever handled
lindane was significantly elevated. The increase in risk for those
who used it as an animal insecticide (Group 1) was OR =1.4
(95% CI 1.0-2.1; p values not stated) and for those who used it
as a crop insecticide (Group 2) was OR = 2.0 (95% CI 1.0-3.7;
p values not stated). The risk for NHL was further increased if
protective equipment was not used while handling lindane to
OR = 1.6 (95% CI 1.0-2.4) for Group 1, and OR = 2.6 (95% CI
1.2-5.5) for Group 2 (Cantor et al., 1992). The OR for NHL
were higher if lindane had been used prior to 1965, OR = 1.7
(95% CI 1.1-2.7) for Group 1, and 2.2 (95% CI 1.0-4.7) for
Group 2 (Cantor et al., 1992). This study suggests an
association between use of lindane and an increased risk for
NHL, and the risk is increased with latency and the lack of
protective equipment. However, in this population, increased
risk for NHL was also observed in association with carbaryl,
chlordane, DDT, dieldrin and malathion exposures. It was not
possible to determine to what extent lindane exposures may
have contributed to the increase in incidence of NHL. A parallel
case-control study of male farmers in these two states, (578 cases
and 1,245 controls) reported a non-significant elevation in the
incidence of leukemia (OR = 1.1) among those who had ever
handled lindane (Brown et al., 1990). In another study of male
farmers from Iowa, in five cases of multiple myeloma and 19
population-based controls matched for age and vital status, there
was no significant increase in the risk for multiple myeloma
(OR = 1.2), in association with lindane exposures from mixing,
handling or applying the pesticide (Brown et al., 1993).
In a later study, data from 987 cases of NHL and 2,895
population-based controls among male farmers from four
Midwestern states (Kansas, Nebraska, Iowa and Minnesota) was
pooled and evaluated for relationships between exposure to
different pesticides and the risk for NHL. Controls were matched
for age, sex, race, state of residence and vital status. The larger
numbers in this study allowed for the computation of the OR for
lindane with and without adjusting for the use of other
pesticides. The OR for NHL associated with lindane use was
significantly elevated (OR = 1.5; 95% CI 1.1-2.0); adjustment
for use of organophosphates, inorganics, diazinon and 2,4-D
reduced the OR observed for lindane use. The authors concluded
that lindane did not appear to play a major role in increasing the
risk of non-HodgkinÕs lymphoma, but a small role could not be
ruled out (Blair et al., 1998).
In another case-control study of 169 male NHL cases and 338
controls in Sweden, the exposure frequency to lindane was too
low to determine an association (Eriksson et al., 1981; Hardell
et al., 1981).
Studies with Exposure to Technical-Grade HCH and Other
Isomers of HCH:
Studies summarized below are of limited value for determining
the carcinogenic potential of lindane since they report on
associations with technical-grade HCH or the most persistent
beta-isomer of HCH, but not pure lindane.
Only one of the studies reviewed suggested a significant
association between exposure to HCH and lung cancer. Male
German agricultural workers (1,658) who had the potential for
exposure to HCH (isomer not specified) and many other
pesticides were observed to have a significant increase in lung
cancer incidence (p < 0.05). The smoking habits of the farmers
were stated to be no different than the general male population
(Barthel, 1981). Although frequently cited, this study does not
provide adequate evidence for a causal relationship between
HCH exposures and lung cancer. While it lists all the chemicals
that were available to the German farmers, exposures could only
be deduced from the length of employment. There were many
chemicals in use during the time of the study, including arsenic,
asbestos, chlorinated dibenzodioxins and DDT.
Other studies have not indicated any significant associations
between exposure to technical-grade HCH and cancer. Median
total HCH levels were increased (37%) in the blood marrow of
six male and seven female cases of leukemia and lymphoma in
comparison with 16 healthy controls, but the increase was not
statistically significant (Scheele and Niessen, 1996). Caldwell et
al. (1981) found that serum levels of beta-HCH in childhood
colorectal carcinoma cases (six males and four females) were not
significantly higher than the levels in healthy siblings and
parents. Another study found no association between higher
levels of HCH isomers in fat tissues from autopsy cases and
mortality from cancer (sex was not specified) (Hoffman et al.,
1967). In a study of adipose tissue from 271 autopsy cases,
higher levels of the beta-HCH were associated with an increased
incidence of primary hepatomas, but only four cases were
analyzed. A statistical analysis was not available for the
association (Radomski et al., 1968).
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3. Cohort Studies:
In a nested case-control study of 32 NHL cases and 158 controls
from an international cohort of pesticide manufacturing workers
and applicators, exposure to lindane was associated with a
small, but not significant increase in the risk for NHL (OR =
1.6; 95% CI 0.3-8.8) (Kogevinas et al., 1995). These workers
had exposures to many other chemicals, making the study
limited in value for establishing an association between lindane
and cancer incidences. Another study evaluated the health effects
of 115 men and three women who were exposed to lindane,
other HCH isomers and organic solvents through their work in a
lindane production plant (average length of service of ten years).
A clinical examination of the liver, kidneys, nervous system and
blood producing organs of these workers did not reveal any
persistent health problems associated with their occupation
(Herbst, 1976).
Many other cohorts that were occupationally-exposed to
technical-grade lindane have been studied for clinical symptoms,
but not cancer incidence (Czegledi-Janko and Avar, 1970;
Duffard and Duffard, 1996; Fleming et al., 1994; Munk and
Nantel, 1977; Nigam et al., 1993; Rayner et al., 1972; Samuels
and Milby, 1971; Srivastava et al., 1995). We recommend that
these cohorts be followed for cancer incidences as well. A study
of 26 farm workers exposed to technical-grade HCH reported no
exposure-related changes in morbidities, but did not provide the
mortality rates from cancer (Srivastava et al., 1995).
4. Summary, Human Studies:
Some case reports have implicated lindane exposures with
leukemia. However, only a non-significant elevation in the
incidence of leukemia was observed in a case-control study of
farmers who had ever handled lindane (Brown et al., 1990). One
study has reported an increased risk of childhood brain cancer
associated with the family use of lindane containing delousing
agents (Davis et al., 1993). This association needs to be
evaluated further using larger sample sizes. One study has
reported a significant increase in the incidence of NHL in
association with lindane exposures, but the potential for
confounding effects different pesticides were not adjusted (Cantor
et al., 1992). A later study that pooled the data from four
Midwestern states found that lindane exposures did not play a
major role in the increase of NHL incidences in this population
(Blair et al., 1998). Two other studies have not found a
significantly increased risk for NHL associated with exposure to
lindane (Kogevinas et al., 1995; Herbst, 1976).
B. Animal Experimental Studies
Most of the studies that have been done to evaluate the
carcinogenicity of lindane would not be considered valid cancer
bioassays due to the small number of animals evaluated
(Fitzhugh et al., 1950; Truhaut, 1954, as cited in IPCS, 1991),
the short durations of treatment (Hanada et al., 1973), or the low
survival rates (Hanada et al., 1973). Many of the studies that
were conducted from 24 to 26 weeks did not show any
associations, but the short treatment periods may not have
allowed time for tumors to develop (Nagasaki et al., 1971;
Nagasaki et al., 1972). For example, in one study hyperplastic
nodules were observed at the end of 26 weeks in mice treated
with lindane, which may have progressed to tumors had the
treatments continued (Goto et al., 1972, as translated by
Vesselinovitch and Carlborg, 1983). Most of the studies that
were done over longer time periods have shown associations
with tumor development. The studies of animals that were
treated for longer periods of time with lindane are summarized
below.
1. Mice
The results of studies that have evaluated the liver
carcinogenicity of lindane in mice are inconsistent. Some
studies have observed an increase in liver tumor incidences in
mice exposed to lindane. In one study, B6C3F1 mice (50/sex)
were fed either a low (80 ppm), or a high (160 ppm) dose of
lindane in diet for 80 weeks and were observed for an additional
10 to 11 weeks (NCI, 1977). The matched controls of 10
untreated mice/sex were combined together to form the pooled
controls. Mice that survived were killed at 90 to 91 weeks. The
incidence of hepatocellular carcinomas was significantly higher
in the males fed the low dose of lindane (19/49, p = 0.001)
compared to the pooled controls (5/49). The incidence of
hepatocellular carcinomas in the males fed the high dose (9/46)
was not statistically different from the matched controls (2/10).
This indicates a lack of a dose-response relationship. No
treatment-related response for hepatocellular carcinomas was
observed for female mice. The survival rates were 88% for males
and 80% for female mice in this study.
The strength of this study was the evaluation for lesions in all
the mice, including unscheduled deaths during the experimental
period. The limitations of this study included the use of pooled
controls from overlapping studies on the carcinogenicity of other
chemicals at the same facility. The body weights of the high
dose group were not affected, indicating that the highest dose
was lower than the maximum tolerated dose (MTD). Only two
dose levels were used, which did not permit an evaluation of a
dose-response effect. The authors concluded that lindane was not
carcinogenic in B6C3F1 mice. Since one out of the two doses of
lindane caused an increase in the number of liver tumors in
treated animals, it is not possible to predict what the outcome
might have been if more and / or higher doses had been used. A
review panel from the IARC (IARC, 1979) criticized the very
low doses used and the small number of animals in the control
group (IARC, 1979).
Thorpe and Walker conducted an experiment in which 29 CF1
mice of each sex received a diet containing 400 ppm of lindane
(a much higher dose than the NCI studyÕs 160 ppm), starting at
one week of age for 109 weeks. Based on histological analysis,
liver tumors were classified as type a or type b. Type a tumors
were described as focal hyperplasia. More progressed lesions,
with evidence of portal-tract involvement were recorded as type
b. Lindane-treated male mice had a significantly increased (p <
0.01) incidence of liver tumors (55% type b; 38% type a; 93%
combined) compared to the controls (23% type a). Among
females, 69% of treated mice had liver tumors (34% type b and
34% type a; 68% combined) compared to controls (23% type a;
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p < 0.01) (Thorpe and Walker, 1973). This study has
limitations since it used only one treatment dose and small
numbers of mice per treatment group.
In contrast, there was no increase in incidence of hepatocellular
carcinomas reported by a study in NMRI mice (50/sex/dose)
that were fed 0, 12.5, 25 or 50 ppm of lindane for 80 weeks
(Herbst and Bodenstein, 1974; Weisse and Herbst, 1977). This
study may not have observed a treatment related effect since it
used very low dose levels of lindane.
Details of a study that has been cited (IARC, 1979; PDR, 1998)
as demonstrating the lack of association between lindane
treatments and development of skin tumors were not available
(Orr, 1948).
Studies That Used Technical-Grade HCH:
Technical-grade HCH (13% lindane) has been found to be
hepatocarcinogenic in Swiss, BALB/c mice and dd mice by
many investigators (Hanada et al., 1973; Kandarkar et al., 1983;
Kashyap et al., 1979; Munir et al., 1983; Nagasaki et al., 1971;
Nagasaki et al., 1972; Nigam et al., 1984). The bulk of
technical-grade HCH is comprised of the alpha-isomer which has
been more frequently associated with hepatocarcinogenicity.
Hence, it is critical that the carcinogenicity of lindane be
evaluated separately. These studies do not provide evidence for a
causal relationship between lindane and hepatocarcinogenicity
and have not been evaluated here.
2. Rats
Most studies on carcinogenicity of lindane in rats have not
found any associations in response to lindane treatments.
However, all the studies that were done would not be considered
valid cancer bioassays. The limitations of the different studies
included short treatment periods (Ito et al., 1975), the use of
only one dose (Ito et al., 1975), small sample sizes (Truhaut,
1954, as cited in IPCS, 1991; Ito et al., 1975; Fitzhugh et al.,
1950); and low survival rates (NCI, 1977).
One study did observe a treatment-related association in
surviving animals, providing limited evidence that lindane
causes thyroid cancer in female rats (NCI, 1977). Groups of 50
Osborne-Mendel rats of each sex were administered a low or a
high dose of lindane for 80 weeks, and then observed for 29 to
30 weeks. Time-weighted average (TWA) dietary concentrations
of lindane were 236 or 472 ppm in males, and 135 or 270 ppm
in females respectively. In males, the survival rate was 60% for
control, 50% for the low-dose and 48% for the high-dose group.
In females, the survival rate was 40% for the controls, and at
least 60% for the low and high-dose groups. The incidence of
liver neoplastic lesions was not significantly increased by
lindane. There was a significant increase (p < 0.05) in the
incidence of thyroid neoplasms (C-cell adenomas) in the low-
dose female group (4/44) compared to the pooled controls
(0/48). A non-significant increase in the incidence of thyroid
neoplasms was observed in the high-dose female group (3/42).
The very low survival rates and the use of only two dose levels
limits the value of this study. The animals may not have lived
long enough to develop late-stage tumors.
3. Dogs
Beagle dogs (4 / sex) fed 25, 50 and 100 ppm /104 weeks, and
200 ppm/32 weeks of technical lindane in diet had a toxic effect,
but did not cause tumors (Rivett et al., 1978). This study was
too small to be considered adequate to demonstrate a negative
association.
4. Summary, Animal Studies:
The results on hepatocarcinogenicity in mice in response to
lindane treatments are inconsistent. While some studies have
not found any hepatocarcinogenic effect in response in lindane
treated mice (Nagasaki et al., 1971; Nagasaki et al., 1972; Ito et
al., 1973c; Goto et al., 1972; Herbst and Bodenstein, 1974;
Weisse and Herbst, 1977), these studies were of limited value as
cancer bioassays because of the small numbers of animals and
insufficient durations of treatments. Other studies have observed
an increased incidence of liver tumors in lindane-treated animals
(NCI, 1977; Hanada et al., 1973; Thorpe and Walker, 1973).
Lindane was found to induce the incidence of liver tumors in
mice, but not in rats. Lindane caused an increase in thyroid
tumors in female rats in one study (NCI, 1977). Three previous
studies in rats had not observed any increase in tumor
incidences, but these studies had used inadequate number of
animals per treatment group (Truhaut, 1954, as cited in IPCS,
1991; Ito et al., 1975; Fitzhugh et al., 1950). Cancer bioassays
that meet current guidelines are needed to address the possible
association of lindane with hepatic carcinomas in mice and
thyroid tumors in female rats.
C. Current Classification of Carcinogenicity by Other
Agencies
1. IARC Classification:
Lindane has been classified in Group 2B, possibly carcinogenic
to humans (IARC, 1987). The evidence for carcinogenicity in
humans has been considered to be inadequate. The evidence for
carcinogenicity to animals is considered limited for lindane, but
sufficient for technical-grade HCH (IARC, 1987).
2. NTP Classification:
Lindane has been classified as reasonably anticipated to be a
carcinogen (NTIS, 1994).
3. EPA Classification:
Lindane is being evaluated for its carcinogenicity in humans
(NTIS, 1994). Based on the weight-of-evidence, EPA assigned
lindane a classification of B2/C (probable human carcinogen)
and a hazard ranking of ÔmediumÕ in 1988 (NTIS, 1994).
V. Critical Evaluation on Breast Carcinogenicity
A. Human Studies
1. Human Tissue Levels
Two case-control studies have evaluated adipose levels of
lindane in breast cancer patients. Neither of these studies
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indicated a significant association between tissue levels of
lindane and breast cancer. However, these studies had many
limitations that are discussed below, and are inadequate for use
in evaluation of a causal relationship.
In a hospital-based study, a small, but not significant elevation
was observed in the mean levels of lindane in the lipids
extracted from nine women with breast cancer (0. 61 ppm in
malignant tissue, and 0.57 ppm in adjacent breast tissue) when
compared to the five presumably healthy women whose deaths
were accident-related (0.39 ppm in breast tissue, and 0.26 ppm
in adjacent adipose tissue) (Wassermann et al., 1976). It should
be noted that lindane was one of several compounds that were
detectable in the tissues of the cancer and control groups. The
very small size of this study prevents a meaningful statistical
analysis. The study was also of limited value since it did not
include any information on the age or lactation history of the
women, factors that could affect the levels of organochlorine
residues in breast tissue.
Adipose tissue from the breasts of five breast cancer patients and
five hospital controls were analyzed for HCH levels (all isomers)
in a second hospital-based study. While higher levels of total
organochlorinated compounds (OCC) were observed in breast
cancer cases, no differences were reported for lindane specifically;
the average levels of another HCH isomer, beta-HCH were
slightly, but not significantly higher in the breast cancer patients
when compared to controls (Djordjevic et al., 1994). This is a
report of a pilot study to show that such a comparison is feasible
using their analytical methods. It included matching the case-
controls for age and the type of breast cancer with respect to the
presence of the estrogen receptor (ER). The small number of
samples analyzed and the lack of details on lindane levels limits
the value of the study. The large-scale study planned by the
authors would be very useful, especially if it also controls for
other risk factors associated with breast cancer risk such as the
reproductive history, weight, height, dietary and tobacco use
habits of the women.
Studies on Adipose Levels of Isomers of HCH Other Than
lindane:
Two small case-control studies have evaluated another HCH
isomer, beta-HCH. While not being very useful in determining
the carcinogenicity of lindane, they are mentioned briefly here to
indicate the need for further studies on the possible relationship
between beta-HCH and breast cancer risk. A hospital-based
study from Finland has presented the analysis of beta-HCH
levels in the adipose tissues of 24 women with breast cancer in
comparison with adipose tissues from 16 cancer-free women that
had died accidental deaths. More women with breast cancer were
nulliparous (child-less) compared to women without breast
cancer. After adjusting for age and parity using stepwise logistic
regression, women with > 0.1 mg/kg of beta-HCH in breast fat
were reported to have a significantly increased risk for breast
cancer (OR 10.51, 95% CI 2.00-55.26, p values not stated)
(Mussalo-Rauhamaa et al., 1990).
In another case-control hospital-based study in Quebec City,
beta-HCH levels in the breast adipose tissue from nine estrogen
receptor (ER)-negative breast cancer cases and nine ER-positive
breast cancer cases were compared to breast adipose tissue from
17 women with benign breast disease (Dewailly et al., 1994).
The average concentration of beta-HCH was the same in the
controls and the ER-positive breast cancer cases (39.7 mg/kg)
and slightly lower in the ER-negative breast cancer cases (34.7
mg/kg). This study used women with benign breast disease as
controls and failed to control for breast cancer risk factors other
than age and parity. The above two studies are inadequate to
draw any conclusions regarding the breast carcinogenicity of
beta-HCH, but indicate the need for further studies including
larger groups of women.
B. Animal Studies:
Animal studies done so far do not indicate a breast carcinogenic
potential for lindane, but most of the studies were of too short
duration and are inadequate to evaluate the breast carcinogenic
potential of lindane.
1. Mice:
Groups of 10 to 11 dd mice of each sex were fed 0, 100 ppm,
300 ppm or 600 ppm lindane in diet for 32 weeks. A low
incidence of mammary carcinomas was reported in females that
were fed the alpha- and beta-isomers (1/8 and 2/8 respectively),
but no mammary carcinomas were reported in the groups of
animals fed lindane. The short duration of treatment may not
have allowed sufficient time for the development of mammary
tumors. The small number of animals used further limit the
value of this study (Hanada et al., 1973). Larger life-time
exposure studies are needed on lindane-treated mice.
2. Rats:
Groups of Osborne-Mendel female rats (50/group) were fed 0,
135 ppm and 270 ppm TWA doses of lindane for 103 weeks
(NCI, 1977). The low dose group was evaluated after 44 weeks,
and the high dose group after 61 weeks; no increase in
mammary gland neoplasms was reported (NCI, 1977). The low
survival rates (40% in controls and 60 % in experimental
groups) weaken any conclusions that can be made from this
study. The animals may not have lived long enough to develop
mammary or other tumors.
3. Summary, Critical Evaluation on Breast Carcinogenicity:
Two human case-control studies have not reported a significant
increase in risk for breast cancer in women with higher levels of
lindane in their breast adipose tissue (Wassermann et al., 1976;
Djordjevic et al., 1994). Both these studies were very small and
are not adequate to assess the breast carcinogenic potential of
lindane to humans.
Animal studies have not reported an increased incidence of
mammary tumors in response to lindane treatments, but the
studies conducted so far were of limited value due to the low
survival rates (NCI, 1977), or short duration of lindane
treatments (Hanada et al., 1973).
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C. Other Relevant Data on Breast Cancer Risk:
1. Evidence of Endocrine Disruption
a) Female Sex Hormone Levels:
In adult female mice, lindane treatments had an adverse effect on
the cholesterol side chain cleavage in the ovaries, a rate limiting
step in steroidogenesis (Sircar and Lahiri, 1990) and suppressed
adrenocortical function (Lahiri and Sircar, 1991). In rainbow
trout hepatocytes, lindane induced the accumulation of estrogen
receptor (ER) and vitellogenin mRNAs, but lindane did not
compete for the ER (Flouriot et al., 1995). Catfish that were
treated with HCH (purity not specified), had significantly
reduced (p < 0.001) plasma levels of sex hormones such as
testosterone, estradiol and estrone (Singh and Singh, 1987).
These studies suggest that lindane disrupts steroidogenesis in
animals.
b) Interference in Estrogen-Mediated Events:
Lindane has been reported by studies in rats, mice, birds and in
vitro assays to interfere with estrogen-mediated events. While
the evidence strongly suggests that lindane causes an interference
in estrogen-mediated events, the mechanism for this action is
not clear. Most studies have found that lindane does not bind to
the ER. There is some evidence that lindane acts as an anti-
estrogen. These studies are discussed below.
i) In Vivo Studies:
Female Fischer rats (eight/group) were gavaged with 0, 5, 10,
20 or 40 mg/kg/day lindane (Cooper et al., 1989). There was a
significant delay in the vaginal opening in females that were
treated with 10 and 40 mg/kg lindane (p < 0.05) and significant
delays in the appearance of regular estrous cycles in almost all
the treated groups (p < 0.02). The estrous cycles in the two
low-dose groups became regular after 90 days and in the two
high dose groups, after 110 days. During the periods of irregular
cycles, both persistent estrus and diestrus were observed. The
pituitary and serum luteinizing hormone (LH) and the serum
prolactin concentrations were significantly lower (p < 0.05) in
females that had received the two higher doses of lindane, but
pituitary follicle stimulating hormone (FSH) levels were higher.
The serum estrogen levels of lindane-treated animals were
significantly increased (p < 0.05) in the group that was fed 10
mg/kg and significantly decreased (p < 0.05) in groups that were
fed 40 mg/kg, and not different in groups that received 5 or 20
mg/kg lindane compared to controls (Cooper et al., 1989). In a
second experiment, prepubertal female rats were gavaged with 30
mg/kg lindane and treated with 10 mg of estradiol benzoate
(EB). The lindane treated females showed a significantly
decreased uterine weight gain (p < 0.05) in comparison with
those that were treated with EB alone. Serum levels of LH and
prolactin were decreased, but pituitary levels of these hormones
was increased. Serum estradiol concentration levels in lindane
treated rats were not different from rats that were given EB alone
(Chadwick et al., 1988; Cooper et al., 1989). The results from
both these experiments suggest an anti-estrogen effect of lindane
and a possible interference in the estrogen-induced release of
pituitary hormones (Cooper et al., 1989).
Lindane administration (0.5 mg/kg) had been reported to cause a
significant (p < 0.05) increase in the length of the estrous cycle
and a reduction in the number of cycles per month in an earlier
study (Naishtein and Leibovich, 1969). Another study observed
that female Fischer rats treated intraperitoneally (i.p.) with 25,
33, 50 or 75 mg/kg lindane on the morning of proestrus had
significantly reduced ( p< 0.05) sexual receptivity in the evening
for females given a dose 33 mg/kg or higher (Uphouse, 1987).
Diestrus treatments (i.p. or p.o.) caused an increase in the length
of estrous cycles and a decrease in the sexual receptivity.
Lindane did not compete with tritiated-estradiol for its receptor,
ER. This suggests that the anti-estrogenic action of lindane is
not due to an interference with estrogen binding its receptor
(Uphouse and Williams, 1989).
In a study involving sexually immature female rats and
ovariectomized estradiol-primed Long-Evans rats, lindane
treatments did not change the serum estradiol concentrations,
induce progesterone receptor, effect a redistribution of ER, or
disrupt the binding of estrogen to its receptor, but did
significantly inhibit (p < 0.05) the estrogen-dependent uterine
weight gain (Laws et al., 1994). This provides further evidence
that lindane is not estrogenic, and may have some anti-
estrogenic effects.
Lindane interfered with implantation during early pregnancy in
Swiss mice, an effect that could be corrected with co-
administration of estrogen (Sircar and Lahiri, 1989). Intragastric
treatments of lindane during mid-pregnancy caused a total
resorption of fetuses, and during late pregnancy, caused reduced
body weights and survival of pups. Suppressed gonadal
steroidogenesis or increased estrogen metabolism by lindane
were suggested as possible mechanisms for this anti-estrogenic
effect (Sircar and Lahiri, 1989).
There is further evidence of lindaneÕs inhibition of estrogen-
effects from experiments in avian species. One day-old chicks
were fed on a diet containing 100 mg /kg lindane for 14 days,
followed by an intramuscular injection of estradiol. The animals
were sacrificed after 24 hours and the oviduct weights and
plasma calcium levels were measured. Lindane caused a
significant inhibition (p = 0.01) of the estrogen-stimulated gain
in oviduct weights and the estrogen-stimulated rise in plasma
calcium levels (Adamec et al., 1974). In another avian study,
daily administration of 20 mg/kg lindane to ducks caused a
delay in the maturation of vitellogenic follicles and ovulation,
and a reduction of the clutch size, indicating an interference with
estrogen-mediated pathways. These effects could be reversed by
an injection of stilbesterol (Chakravarty et al., 1986).
Hybrid rabbits that were given 0.8 mg/kg lindane by gavage for
12 weeks were found to have a significantly reduced (p <0.05)
ovulation rate, suggesting an interference in endocrine pathways.
This effect was not seen if lindane treatments were combined
with a 3 mg/kg dose of DDT (Lindenau et al., 1994). Some
forms of DDT are weakly estrogenic. Inhibition of ovarian
growth and impaired ovulation with lindane treatment has also
been reported in catfish (Singh et al., 1993). In another study,
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lindane did not to compete for the ER, but did significantly
inhibit (p = 0.05) DNA synthesis in cultured bovine oviductal
and uterine cells (Tiemann et al., 1996). In an artificial
transactivation system in yeast, > 1 mM lindane was found to
significantly inhibit (p < 0.05) the transactivation of a
progesterone-sensitive reporter. This effect was not through a
direct interaction with the progesterone receptor itself (Jin et al.,
1997).
In contrast, one study has reported a weak estrogenic effect.
Lindane fed ovariectomized albino rats had significantly
increased glycogen (p < 0.05) in their uterus, cervix and vagina,
but no histopathological changes or increase in organ weight
(Raizada et al., 1980). The authors describe this as a weak
estrogenic effect but, this conclusion is based on an increase in
organ glycogen content alone and adequate tests of estrogenicity
were not conducted to confirm this observation.
ii) In Vitro Assays for Estrogenicity:
Lindane does not appear to be estrogenic, as determined by its
inability to stimulate proliferation of MCF-7 cells (an estrogen-
dependent breast tumor cell line) in the E-SCREEN assay for
estrogenicity (Soto et al., 1995). Lindane was neither estrogenic
or anti-estrogenic in an in vitro assay for the induction of the
estrogen-responsive gene apolipoprotein II. This study is only
evaluated one of several estrogen-mediated responses
(Ratnasabapathy et al., 1996; Ratnasabapathy et al., 1997). A
major metabolite of lindane from rat microsomes, 2,4,6-
trichlorophenol (TCP), did not mimic estrodiol. In contrast,
another HCH isomer, beta-HCH (1mM) did induce progesterone
receptors and caused redistribution of ERs in MCF-7 cells
(Coosen and van Velsen, 1989). Since beta-HCH is not
considered to be a major metabolite of lindane, this result is not
relevant for lindane.
c) Male sex hormone levels:
Exposure to lindane among 60 male workers at a chemical
factory was associated with significantly higher (p < 0.01)
luteinizing hormone (LH) levels in their serum, but testosterone
levels were not affected (Tomczak et al., 1981). In male rats,
lindane significantly inhibited (p < 0.001) the formation of 5a-
dihydrotestosterone-receptor complex in the prostrate cytosol
(Simic et al., 1991). This effect was completely reversible in a
week after the treatment was stopped. These studies indicate that
lindane may also affect steroid-mediated pathways in males.
d) Summary, Endocrine Disruption:
Studies in rats, birds, rabbits and catfish suggest that lindane
disrupts the reproductive cycles (Cooper et al., 1989; Chadwick
et al., 1988; Naishtein and Leibovich, 1969; Uphouse, 1987;
Uphouse and Williams, 1989), interferes with estrogen-mediated
effects such as uterine-weight gain (Cooper et al., 1989;
Chadwick et al., 1988; Laws et al., 1994), ovulation (Adamec
et al., 1974; Chakravarty et al., 1986; Lindenau et al., 1994;
Singh et al., 1993) and implantation during early pregnancy
(Sircar and Lahiri, 1989). Lindane treatments caused delays in
vaginal opening (Cooper et al., 1989) and inhibited the release
of pituitary gonadotropins (Cooper et al., 1989; Chadwick et
al., 1988). In in vitro assays, lindane interfered with the
induction of a progesterone-sensitive receptor (Jin et al., 1997)
and with the estrogen-mediated induction of DNA synthesis in
bovine oviductal and uterine cells (Tiemann et al., 1996). A
lack of an estrogenic effect is supported by three studies on
lindane (Soto et al., 1995; Ratnasabapathy et al., 1996;
Ratnasabapathy et al., 1997) and one study that evaluated a
lindane metabolite (Coosen and van Velsen, 1989) These
studies support the conclusion that lindane is not estrogenic and
may have some anti-estrogenic action. The only evidence
suggesting a weak estrogenic effect for lindane came from a study
that showed that it increased the uptake of glycogen in an
estrogen-responsive reproductive tissue (Raizada et al., 1980).
The mechanism by which lindane exerts its anti-estrogenic
effects is not clear. Several studies have reported that lindane can
disrupt steroidogenesis (Tomczak et al., 1981; Sircar and
Lahiri, 1989; Cooper et al., 1989; Sircar and Lahiri, 1990;
Lahiri and Sircar, 1991; (Singh and Singh, 1987). LindaneÕs
anti-estrogenic effects do not involve its binding to the ER.
Several studies have indicated that lindane does not compete
with tritiated-estradiol for its receptor (Uphouse and Williams,
1989; Laws et al., 1994; Flouriot et al., 1995; Tiemann et al.,
1996). However, one study has reported an interference in
estrogen-ER binding by lindane (Tezak et al., 1992). There has
been a recent report on the identification of a new estrogen
receptor called the beta-receptor (Kuiper et al., 1996). Whether
lindane interacts with this receptor needs to be determined.
While it appears that lindane is an endocrine disruptor, the
disuptions caused by lindane do not appear to have an
estrogenic effect in animals, and are not the kind that have been
linked with an increase in breast cancer risk.
2. Reproductive and Teratogenic Effects:
A study of women exposed to pesticides, including lindane, did
not report any adverse effects on pregnancy outcomes (Willis et
al., 1993). Adipose tissues of still born infants and those that
died soon after birth (n = 12), and cord blood samples from
normal full term pregnancies (n = 30) did not differ significantly
in the levels of lindane (Curley et al., 1969). No teratological
effects were observed in mice that were treated with a mixture of
thimet/pthorate and lindane (oral dose, 1.40 mg/kg) (Savkovic
et al., 1985). Lindane administrations (5, 10 and 15 mg/kg
body weight) to CFY rats did not cause any teratogenic effects
(Palmer et al., 1978). Benesan¨ (50% lindane), administered to
pregnant rats (oral/day, 6.25, 12.5 or 25 mg/kg during 6th-15th
day of pregnancy), did not affect fetal development adversely
(Khera et al., 1979a; Khera et al., 1979b). Lindane was not
teratogenic or affect the litter size in dogs. However, it did
increase the percentage of still born pups. A statistical analysis
was not presented (Earl et al., 1973).
A study of Fischer rabbits (n = 5) treated with 0.8 mg/kg
lindane observed that lindane did accumulate in the genital tract
tissues of the treated animals and interfered with their ovulation.
The fertilization rates were not different in treated animals
compared to controls (Lindenau et al., 1994; Seiler et al.,
1994). While most studies have not observed that lindane has
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any teratogenic or developmental effects, its interference with
ovulation in rabbits further supports its ability to disrupt
endocrine pathways.
In spite of all the above negative results for teratogenic effects in
animal studies, because of the ability of lindane to cross the
placenta, physicians prefer to use precipitated sulphur instead of
lindane in topical treatments of the mucosal areas of pregnant
women against ectoparasites. Since small amounts of lindane
can be secreted in breast milk after topical treatments, physicians
recommend that lactating women use alternate methods to feed
their infant for two days after topical treatments with lindane
(Stockton and Paller, 1990).
3. Tests of Mutagenicity:
The results from studies on the mutagenic potential of lindane
in whole animals and in isolated cells are inconsistent. While
lindane was found to be mutagenic in isolated cells in some
studies, it was not found to be mutagenic by most assays in
animals or bacteria. The results of these studies are summarized
below.
a) Chromosome Aberrations in Occupationally-Exposed
Humans:
Manufacturing workers exposed to lindane (males), were not
observed to have an increased frequency of chromosome
aberrations in their lymphocytes (Kiraly et al., 1979). Another
unpublished study of lymphocytes from occupationally exposed
humans by Desi et al., 1972, has been cited to have similar
findings (IPCS, 1991). Details on the study design were not
available.
b) Studies in Animals:
Frequency of chromosome aberrations were not increased in
herds of pigs with high exposure to insecticides including
lindane. The evaluation of exposure was very crude, through the
analysis of selected substances in sedimented dust collected in
the fattening rooms (Rubes, 1987).
No effect of lindane treatment was observed in mice on the
frequencies of micronuclei (Jenssen and Ramel, 1980) or sister
chromatid exchanges (SCE) (Guenard et al., 1984, as cited in
IPCS, 1991). A single oral dose of a mixture of thimet/pthorate
and lindane (1.40 mg/kg) was not mutagenic to mice (Savkovic
et al., 1985). Frequency of chromosomal aberrations in the bone
marrow cells of Syrian hamsters was unchanged following
treatments (i.p.), with a commercial preparation of lindane
(10%) (Dzwonkowska and Hubner, 1986). In another study, i.p.
injection of 50, 75 or 100 mg/kg of lindane caused a significant
increase (p < 0.05) in chromosome aberrations and micronuclei
in the bone marrow cells of chickens (Bhunya and Jena, 1992);
oral administration of the same doses caused only a non-
significant increase in chromosome aberrations (Bhunya and
Jena, 1992). A significant increase (p < 0.05) in single stranded
breaks (SSB) was observed in DNA extracts of hepatic nuclei
from lindane-treated female rats (per oral dose of 30 mg/ kg)
(Hassoun et al., 1993). The significance of SSB in predicting
the mutagenic potential of lindane is not clear. Lindane, injected
as a 0.001% solution, was unable to induce sex-linked recessive
mutations in Drosophila melanogaster (Benes and Sram,
1969).
c) Studies in Isolated Cells:
i) Evaluations of Transformation Frequencies:
Lindane treatments at 100 , 50 and 10 mg/ml, increased the cell
transformation frequency of BALB/c 3T3 cells significantly and
in a dose dependent fashion (p < 0.05 at lower two doses, to p
< 0.01 at the highest dose) (Perocco et al., 1995). This
transformation ability of lindane needs further evaluation with
other cell lines. In a study that assayed mutation rate as the rate
for acquiring resistance to 6-thioguanine, lindane did not
significantly increase the mutation rate of Chinese hamster V79
cells (Tsushimoto et al., 1983).
ii) Evaluations of Potential for DNA-Damage:
In cultured human peripheral lymphocytes and in rat
thymocytes, a 500 mg/ml dose of lindane caused an increase in
unscheduled DNA synthesis (p values not stated) and an
inhibition of the cell repair processes following UV radiation,
thus increasing the potential for mutations (Rocchi et al., 1980).
In another study, unscheduled DNA synthesis was not found to
be induced by lindane in cultured human fibroblast cells
(Ahmed et al., 1977).
Lindane caused a slight increase in the frequency of chromosome
breaks and gaps in Chinese hamster fibroblasts. Increase in
polyploidy was not observed with lindane treatments and it was
classified in the ÒsuspiciousÓ group among 134 chemicals that
were screened for mutagenicity in this study (Ishidate and
Odashima, 1977). No DNA damage was detected in another
study using a single-cell gel electrophoresis assay of cells from
mice that were treated with technical-grade HCH (Sasaki et al.,
1997). A formulation of technical HCH containing 6.5% lindane
was found to cause a significant increase (p < 0.05) in
chromosome aberrations and SCE in human peripheral
lymphocytes in one study (Rupa et al., 1989). Note that this
study did not use pure lindane and the effect could be due to any
of the other HCH isomers. In another study, lindane caused a
suppression of cell division and induced chromatid breaks in
human peripheral blood lymphocytes; details on this study were
not available and it was declared inadequate by the WHO
(Tzoneva-Maneva et al., 1971, as cited in IARC, 1979).
Human nasal mucosal cells (NM) were found to be more
sensitive to genotoxic effects of lindane than human gastric
mucosal cells. Lindane (0.5 mm/ml) caused a significant
reduction (p < 0.01), in the percentage of intact NM cells from
rats and humans. The authors suggest that inhaled lindane may
thus be more damaging to humans than the lindane consumed
in food (Pool-Zobel et al., 1994). DNA-damage in this study
was detected as alterations in the electrophoretic mobility of the
DNA liberated after cell-lysis. However, chemicals are known to
alter DNA-mobility in an electrophoretic assay without being
mutagenic (for example, high salt concentrations). The
possibility that increasing lindane concentrations could affect its
electrophoretic mobility by changing the effective electric current
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to which it is exposed, but not necessarily causing DNA
damage, was not addressed in this study.
A meeting abstract reported that lindane caused chromosome
breakage in cells, but did not provide details about the assay
system (Grant, 1973). Lindane was found to increase the in vitro
rate of tubulin assembly in porcine brain cells by 30%.
Although disrupted rate of tubulin assembly could theoretically
cause aneuploidy, such an effect was not assayed for in this
study (Albertini et al., 1988).
Studies have looked for a direct interaction of chemicals with
DNA as evidence supporting their role in causing DNA-damage.
In two studies lindane was found to bind to DNA very weakly
(Gopalaswamy and Nair, 1992; Iverson et al., 1984). However,
this negative result does not necessarily indicate that lindane is
not genotoxic, since a direct macromolecular interaction may
not be necessary for a genotoxic effect. This was demonstrated in
a comparative study in which the alpha-isomer had a three fold
lower DNA-binding ability than lindane, but a greater potency
for tumor induction in the liver of mice that were exposed by
oral gavage (Sagelsdorff et al., 1983).
d) Studies in Bacteria and Yeast:
Gamma-BHC was unable to revert auxotrophic mutants of E.
coli  or Salmonella typhimurium (Ashwood-Smith, 1972;
IPCS, 1991), and was not mutagenic to yeast (Fahrig et al.,
1974, as cited by Moutschen-Dahmen et al., 1984). Similar
results were reported for a HCH mixture (IARC, 1979; Shirazu
et al., 1976). A commercial formulation that included lindane
(Lindex, 4.5% lindane), increased the frequency of prototrophic
revertants in yeast, but this effect could be due to any of the
other HCH isomers.
e) Summary, Mutagenicity:
Lindane exposures were not associated with mutagenic effects in
studies of exposed human populations (Kiraly et al., 1979;
IPCS, 1991) and most studies in animals (Rubes, 1987;
Jenssen and Ramel, 1980; IPCS, 1991). One study has
indicated an increase in the number of transformed foci in
BALB/c 3T3 cells in response to lindane (Perocco et al., 1995).
This result needs verification with other cell lines. Most of the
studies have evaluated the potential of lindane to cause DNA
damage (Rocchi et al., 1980; Ahmed et al., 1977; Ishidate and
Odashima, 1977; Sasaki et al., 1997; Rupa et al., 1989; Pool-
Zobel et al., 1994) without adequate evidence to show that it
actually does damage DNA in animals. Studies of the
mutagenicity of lindane in animals, bacteria and yeast do not
support a strong genotoxic effect.
4. Evidence of Tumor Promotion
There are many reports on the tumor promotion ability of
technical lindane (Munir et al., 1984). Since technical lindane
consists of isomers that have been reported to have a tumor
promotion effect, it is essential to evaluate pure lindane
separately.
One study found increased tumors in liver and lungs of lindane
treated mice, but only in mice of a specific genetic background.
Dominant mutations at the agouti locus, Avy can be
phenotypically expressed as the Òobese yellowÓ or the Òlean
pseudoagoutiÓ. Obese yellow Avy/a, pseudoagouti Avy/a, and
lean black a/a  female mice were fed 160 ppm lindane for 6, 12,
18 or 24 months. Tumor incidences in animals treated with 160
ppm lindane for 24 months are presented in Table 1.
The yellow mice had statistically increased incidence of tumors
when compared to black mice even in the absence of lindane
treatments, indicating an effect of the mutation at the agouti
locus. Lindane treatments caused a statistically significant dose-
related increase (p values for increases caused by lindane-
treatments were not stated) in the number of liver adenomas,
combined liver tumors, lung hyperplasia and tumors. While
obesity may be a factor for the increased incidence of tumors
observed in the yellow mice, the higher incidence of the tumors
in the lean pseudoagouti mice suggests a possible role of the Avy
mutation in affecting lindaneÕs metabolism or the cellÕs
susceptibility to lindane or its metabolites (Wolff et al., 1987).
A different study has reported that yellow mice have increased
tissue storage of lindane and its polar metabolites with
increasing age and obesity (Chadwick et al., 1985). The tumor
promotion effect of lindane needs to be tested in non-genetically
altered strains of experimental animals.
Another study evaluated the cytopathological effects of the
combined topical application of 18 mg lindane (purity
unspecified) and 9.1 mg of the insecticide diazinon on 80 female
albino rats. No macroscopic changes were seen on application of
either compound separately, but a synergistic interaction was
proposed due to the enhanced cytopathological changes visible
in the epidermal layer after combined applications (Dikshith et
al., 1974). A study of dd mice that were fed a combination of
250 ppm lindane and 250 ppm polychlorinated biphenyls
(PCBs) in diet for 24 weeks did not observe a higher incidence
of liver tumors in animals fed a combination of both chemicals
when compared to the incidence of liver tumors in animals that
were fed each compound separately (Ito et al., 1973a; Ito et al.,
1973b).
Stimulation of DNA synthesis may be an indicator of a tumor
promotion-event. Lindane did not stimulate DNA synthesis in
the liver of rats or mice that were given 1 mM/kg lindane by
oral gavage (Busser and Lutz, 1987). Another possible
mechanism that is being evaluated for hepatic tumor promotion
is the induction of protein kinase C (PKC) activity; lindane was
found to be a potent stimulator of the activity of purified PKC in
vitro (Moser and Smart, 1989).
Other studies have evaluated the promotion ability of lindane by
quantitating the induction of g-glutamyltranspeptidase (GGT)
positive liver foci. Lindane increased the number GGT-positive
foci in the livers of partially hepatectomized female Sprague-
Dawley rats that were initiated with 0.3 mM/kg of
diethylnitrosamine (DEN) (Kitchin et al., 1994; Pereira et al.,
1982). Another study has reported that 30 mg/kg lindane in diet
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State 11
Table 1. The Effect of Lindane Treatments on Mice Carrying the Avy Mutation
Tumor Type Phenotype Genotype Control Treated
Liver adenomas Y
P
B
Avy/a
Avy/a
a/a
9%
5%
6%
35%
12%
3%
Liver carcinomas Y
P
B
Avy/a
Avy/a
a/a
13%
2%
3%
17%
5%
1%
Combined (liver adenomas
and carcinomas)
Y
P
B
Avy/a
Avy/a
a/a
22%
7%
9%
52%
17%
4%
Lung hyperplasia Y
P
B
Avy/a
Avy/a
a/a
15%
10%
10%
72%
76%
82%
Lung tumors Y
P
B
Avy/a
Avy/a
a/a
4%
6%
2%
19%
14%
3%
Y = yellow
P = pseudoagouti
B = black
The statistical analysis done in this study analyzed the increases in incidence in response to the mutation, but not in response to
lindane treatments (Wolff et al., 1987), and have not been included here.
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for 15 weeks could significantly enhance (p < 0.05) GGT-
positive foci and have more potent an effect than the positive
control phenobarbitol (Schroter et al., 1987). These studies
indicate mechanisms that may lead to the promotion of hepatic
tumors in lindane treated animals.
A study reported that liver microsomes of lindane-fed mice and
rats, metabolize aflatoxin B1 (AFB1) into more mutagenic
metabolites (Decloitre and Hamon, 1980). In contrast, in
another study, lindane treatments caused a complete inhibition
of the incidence of aflatoxin B1 (AFB1) induced liver tumors in
female Buffalo rats (Angsubhakorn et al., 1989). The authors of
both studies suggest that lindane alters the liver metabolism of
AFB1. Besides the conflicting results of the above two studies,
a third study reports that lindane does not significantly alter the
metabolite profile of benz[a]anthracene in rats, suggesting no
effect on liver enzymes involved in the metabolism of this
carcinogen (Jacob et al., 1985).
5. Signal Transduction and Intercellular Communication
Cells use intercellular communication to regulate their growth.
Disruption of intercellular communication is a mechanism that
has been suggested to lead to cell transformation. Lindane
caused a significant inhibition (p < 0.001) of the intercellular
communication in rat uterine myocytes (Criswell and Loch-
Caruso, 1995). It caused an inhibition in intercellular
communication in Chinese hamster V79 cells as well, but at
much higher concentrations (15 mg /ml) than the concentration
of tumor promoter control 12-O-tetradecanoylphobol-13-acetate
(TPA) that was required for the inhibition (0.1 mg/ml)
(Tsushimoto et al., 1983). Another study reported a significant
and dose-responsive (p < 0.05) decrease in intracellular
communication of mouse hepatocytes at non-cytotoxic
concentrations of lindane (Ruch et al., 1987). The inhibition of
communication was reversible when lindane was removed
(Klaunig et al., 1990). No studies were found that evaluated the
ability of lindane to disrupt intercellular communication in
mammary cells.
6. Effects on Hepatic Microsomal Hydroxylases
Interspecies differences in hepatic metabolism have been
investigated to explain why mice are more susceptible to hepatic
tumors than rats to lindane treatments in cancer bioassays. One
study has observed that the hepatic mitochondrial extracts from
female rats had significantly elevated (p < 0.05) microsomal
lipid peroxidation rates following lindane treatment (p.o., 30
mg/kg) (Hassoun et al., 1993). Another study reported that
hepatocarcinogen-initiated liver cells from mice (from partial
hepatectomies and neoplastic nodules), were more resistant to
the cytotoxic effects of lindane than similar cells from rats (Ruch
et al., 1985). Higher accumulations of reactive and mutagenic
metabolites in mice was suggested as a possible reason for their
greater susceptibility to developing liver tumors in response to
lindane treatments. However, subcellular liver preparations from
mice and rats treated with lindane were both found to be
negative for any mutagenic activity in S. typhimurium by a
different study (Glatt and Oesch, 1987).
7. Immunological Effects:
A compromised immune system may decrease the host defenses
against cancer. There is limited evidence that lindane treatments
may suppress the immune response to mitogens in animals. In
one study, female BALB/c mice (6/dose) were fed 0, 0.012,
0.12 and 1.2 mg /kg/day of lindane for 24 weeks. The
lymphoproliferative response to Con A (a mitogenic stimulus)
was observed to have a biphasic curve in treated mice; there was
a significant stimulation (p < 0.001) in the lymphoproliferative
response during the first four weeks of treatment and significant
suppression (p < 0.005) after continued lindane treatment at the
two higher dose levels (Meera et al., 1992). Further studies are
needed to determine if chronic exposures to lindane cause a
suppression of experimental animalsÕ immune-response to
mitogens, and if the immuno-suppression leads to an increased
susceptibility to cancer.
In another study, male albino mice were fed 0, 10, 30 or 50
ppm lindane. The mice fed 50 ppm lindane had a significantly
reduced (p < 0.05) primary and secondary antibody titer to
sheep red blood cells (SRBC) after 3, 6, 8 or 12 weeks of
treatment (Banerjee et al., 1996). Similar results were observed
in a study of Charles Foster albino rats (5 rats/sex/dose) given
6.25 and 25 mg lindane by gavage for five weeks. A decreased
immune response to the Salmonella vaccine was observed in
comparison to untreated rats (stated by authors as significant; p
value not available) (Dewan et al., 1980). A significant
suppression in immune response (stated by authors as
significant; p value not available) was also reported in a study of
rabbits exposed to capsules containing 1.5, 6 and 12 mg/kg/day
of lindane, five times a week for five to six weeks (Desi et al.,
1978). These studies indicate a general immune suppression of
animals in response to lindane treatments. However, the
mitogenic response of these immune-suppressed animals was
not tested.
Lindane stimulated human polymorphonuclear neutrophils
(PMN) in vitro, causing an increase in the production of
superoxide anions. While the cidal action of the PMN involves
production of superoxide anions, the effect of this strong
nonphysiological stimulation by lindane has not been tested in
whole animals (Kuhns et al., 1986).
Studies that have evaluated the immune responses in
experimental animals suggest immuno- suppression effects
caused by lindane treatments. Future animal modeling studies
need to determine if lindane exposure can affect the immune
response of animals to challenges with transplantable mammary
tumor cells in multiple species, including the rat and mouse.
8. Summary of Other Relevant Data on Breast Cancer Risk:
Lindane was not mutagenic in most animal and bacterial
systems studied. The potential for DNA damage and cell
transformation by lindane observed in in vitro systems needs
further investigation. Lindane can act as a promoter for lung and
liver tumors in mice carrying the Avy mutation at the agouti
locus. Lindane was not estrogenic in in vitro assays, and its
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disruption of estrogen-mediated events and steroidogenesis in
animals supports that it has some anti-estrogenic effects.
Lindane has been found to disrupt intercellular communication
in mammalian cells and suppress the lymphoproliferative
response to mitogens in mice. These mechanisms need to be
evaluated further for their impact on tumor promotion and breast
cancer risk in animals.
VI. Other Information
A. Environmental Fate and Potential for Human
Exposure:
Lindane adsorbs to organic matter in the soil, causing its
mobility to be very slow in organically rich soils. The half-life
of lindane can vary considerably depending on the type of soil
and temperature. Different studies under different soil conditions
have reported half-life for lindane that ranges between 12 days to
1,146 days (IPCS, 1991).
1. Occupational Exposure:
Workers in a technical-grade HCH formulation plant were found
to have uniformly high levels of pesticide on their skin (Wolff et
al., 1992). Dermal exposure from exposed forearms and contact
with contaminated clothing was found to be a major exposure
routes during handling of lindane-treated seeds (Fenske et al.,
1990). Lindane can be absorbed through the skin at an
absorption rate of 9.3% (Feldman and Maibach, 1974). Its
absorption from tropical treatments is increased when applied
with a fatty-like base or to damaged skin (Solomon et al., 1977;
Zesch, 1986). Blood levels of 57 male manufacturing workers in
Germany indicated elevated levels of lindane (median = 23
mg/L) among all the exposed workers (Baumann et al., 1980).
Blood levels of lindane among 71 agricultural workers were not
found to be different than non-exposed controls (Rosell et al.,
1993). The mean levels of lindane in the blood of exposed
malaria spraymen was not found to be increased, but the total
HCH levels were elevated (Gupta et al., 1982).
2. Potential for Exposure for the General Population:
The beta-isomer is the most persistent isomer of technical
lindane. Lindane itself is rapidly broken down in warm-blooded
animals and disappears within three weeks of the removal of
HCH from animal diet (Davidow and Frawley, 1951).
Although the main source of exposure to lindane for the general
population is through contaminated food, the amounts of
lindane that are estimated to be present in the average diet in the
U.S. have been decreasing steadily and are not considered to be
a health concern (IPCS, 1991). Lindane is very stable in both
freshwater and sea-water (Sieper, 1972). Animal feeding studies
have indicated some storage of lindane in the fat tissue
(Davidow and Frawley, 1951). These studies together suggest
that lindane residues from water may have contaminated fish in
the past. A survey of fish caught in U.S. rivers and Great Lakes
found the maximum wet weight residue concentration of lindane
to have decreased from 0.30 mg/g in collections during 1976 to
1977, to 0.04 mg/g in samples obtained in 1984. However,
lindane has been found to occur in more than trace levels at
some stations, indicating recent inputs (Schmitt et al., 1990).
Lindane exposure can also occur through dermal absorption in
children treated for head lice with Kwell¨ shampoo. Lindane
could be detected in the blood of treated children two to 24
hours after application of Kwell¨ (Ginsburg and Lowry, 1983).
Lindane treatments are now restricted for use against head lice
and are prescribed by physicians for patients who have failed to
respond to other approved therapies. The manufacturerÕs
instructions warn against effects of overdoses and the use of
lindane products along with oil-based treatments (PDR, 1998).
In summary, while there is the potential for exposure to trace
amounts of lindane from food, lindane does not persist in the
environment or bioaccumulate in animal fat to cause prolonged
exposures. The ability of lindane to be absorbed through the
skin indicates the need for caution in application of lindane
containing prescription products. Based on the average dose rate
from air, food and water, and the oncogenic potency factor for
lindane, Kastenberg and Yeh have calculated the oncogenic risk
for a 15-yr average exposure to be 7.4 x 10-7 (7.4 in ten million)
(Kastenberg and Yeh, 1993).
3. Storage and Excretion of Lindane in Humans:
Lindane residues were detected in the fat, breast milk and blood
samples of humans in the late 1960s and 1970s. Amounts of
lindane that are estimated to be present in the average diet in the
U.S. have been decreasing steadily and this is reflected in the
decrease in lindane levels that are detectable in human milk and
adipose tissue in the U.S.
a) Human Milk and Lactation:
The beta-isomer of HCH is however much more persistent and
still detectable in 27% of human milk samples tested from
Arkansas women (Jensen, 1991). Studies of human milk
samples from most European countries indicate low levels of
HCH in general (average around 0.2 ppm in fat), with relatively
higher levels in Czechoslovakia, France and Italy. Human milk
samples from Asia, particularly from India and China have very
high levels (average 6 ppm in fat) of total HCH. The levels in
Japan have decreased gradually, but are still higher than
European levels (Jensen, 1991). The levels of lindane in the
human milk of residents in Zimbabwe were lower than DDT
levels, but detectable in 61% of the samples analyzed (Chikuni
et al., 1991).
A 1979 study had observed that the lindane levels in breast
milk samples from 100 women in Colorado were higher than
the levels found in cowÕs milk (Macy et al., 1979). However,
lindane levels of American breast milk samples have been
declining since its agricultural use has been virtually eliminated
over the past two decades (Sonawane, 1995). The very small
amounts of lindane that have been found in breast milk samples
in the U.S. are not considered a health concern for infants that
are breast-fed (IPCS, 1991).
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Studies have analyzed lindane levels before and after lactation to
determine if lactation is an effective means of excretion of
lindane. A study compared the blood and milk samples from
five pregnant women before and after lactation for HCH levels.
The blood levels of HCH were not significantly lowered after
lactation in this study (Curley and Kimbrough, 1969). Other
studies have observed milk levels of lindane to decline after
lactation suggesting a reduction in the body burden after
excretion of lindane in breast milk (Dillon et al., 1981; Klein et
al., 1986).
A study of fat tissue from 50 children in Germany that had
undergone surgery in the early 1980s, indicated that 98% of the
children had detectable levels of lindane in their adipose tissue.
The authors conclude that the levels were reflective of transfer of
lindane through breast milk, but samples of adipose tissue of
bottle-fed infants were not available for comparison (Niessen et
al., 1984).
b) Adipose Tissue:
Lindane residues were detectable in 88% of the human adipose
samples analyzed in Canada in the 1970s (Ames, 1979). A
study of adipose tissue samples of 25 persons (19 males and 6
females) from Texas in the mid-1980s found lindane residues in
96% of the samples, with a mean level of 0.20 ppm (Redetzke
and Applegate, 1993). No breakdown products were detected.
The results in Texas were suggestive of a recent (since there
were no breakdown products) dispersed source for lindane, such
as food or water.
In a study of levels of organochlorine pesticides in the adipose
tissue of 51 human fat samples from a New Zealand hospital, the
levels of DDT were found to increase with age, but lindane
residues were found to decrease with age (Solly and Shanks,
1974). This result is in agreement with a study done on the
blood organochlorine pesticide residues in Virginia residents
(Griffith and Blanke, 1975). These studies indicate that lindane
does not persist in the human body for extended periods of time.
4. Excretion and Metabolism of Lindane in Animals:
Lindane-fed rats were found to excrete 39% of the insecticide in
an unmodified form in urine and feces (Rao et al., 1975). The
first step in lindane metabolism leads to a substantial
detoxification, but the second step results in the formation of
active metabolites (Engst et al., 1976). Di-, tri-, and tetra-
chlorophenols have been identified as lindane metabolites, but
all possible products have not been identified (Chadwick and
Freal, 1972; Grover and Sims, 1965). Lindane and alpha-HCH
are both metabolized in part to beta-pentachlorocyclohex-1-ene
(beta-PCCH) by microsomal mono-oxygenases. A stable
metabolite, beta-PCCH epoxide is acutely toxic to Salmonella,
making it difficult to test for mutagenicity (Fitzloff and Pan,
1984). Pretreatments with DDT stimulated the metabolism of
lindane in rats, but via alternate pathways (Chadwick et al.,
1977). One study indicated the presence of HCB as a
metabolite, but this result has been debated (Smith, 1991).
There is no significant interconversion of HCH isomers during
their metabolism (Waliszewski, 1993).
VII. Summary and Recommendation for Breast
Carcinogenicity Classification:
There is inadequate evidence to classify lindane as a Òhuman
breast carcinogenÓ. We propose that it should be classified in
Group 3, not classifiable as to its breast carcinogenicity to
humans (see Appendix B for BCERF breast carcinogenicity
classification scheme). We base this conclusion on the following
evidence: Human studies are inadequate to conclude that lindane
exposure directly causes breast cancer in women. Case-control
studies on the breast carcinogenicity of lindane in humans are
inadequate because they were based on very few breast cancer
cases (14 total in the two studies) (Wassermann et al., 1976;
Djordjevic et al., 1994). The evidence from long-term animal
cancer bioassays is not adequate to evaluate lindaneÕs mammary
carcinogenicity. Although experimental animals that were
treated with lindane have not shown an induction of mammary
gland tumors (NCI, 1977; Hanada et al., 1973; Thorpe and
Walker, 1973), many of the animal studies were not adequate
cancer bioassays because of their short duration (Hanada et al.,
1973; Nagasaki et al., 1971; Nagasaki et al., 1972; Ito et al.,
1975; Goto et al., 1972; Rivett et al., 1978), small sizes
(Fitzhugh et al., 1950; Truhaut, 1954, as cited in IPCS, 1991;
Hanada et al., 1973; Thorpe and Walker, 1973) and low
survival rates (NCI, 1977). Consequently, we conclude that the
evidence for breast carcinogenicity of lindane is inadequate in
humans and in animals.  
However, there is limited evidence from other relevant data on
mechanisms by which lindane may affect breast cancer risk.
Lindane can act as a lung and liver tumor promoter in
genetically altered mice (Wolff et al., 1987). Lindane has been
found to disrupt intercellular communication in mammalian
cells (Criswell and Loch-Caruso, 1995; Tsushimoto et al.,
1983; Ruch et al., 1987) and suppresses the mitogenic response
of the immune system in mice (Meera et al., 1992). Further
research is needed to test if lindane can promote breast cancer
through these mechanisms.
There is other evidence that indicates that lindane may not affect
breast cancer risk. Lindane does not appear to be estrogenic in
both in vivo (Cooper et al., 1989; Chadwick et al., 1988;
Naishtein and Leibovich, 1969; Uphouse, 1987; Uphouse and
Williams, 1989; Laws et al., 1994; Adamec et al., 1974;
Lindenau et al., 1994; Singh et al., 1993) and in vitro assays
(Soto et al., 1995; Ratnasabapathy et al., 1996; Ratnasabapathy
et al., 1997). There is evidence that lindane can disrupt
hormonal pathways. These disruptions of estrous cycles and a
suppression of estrogen-mediated release of pituitary hormones
in rodents (Cooper et al., 1989; Chadwick et al., 1988), a
suppression of ovulation (Adamec et al., 1974; Chakravarty et
al., 1986; Lindenau et al., 1994; Singh et al., 1993) and
implantation during early pregnancy (Sircar and Lahiri, 1989).
Lindane treatments caused delays in vaginal opening (Cooper et
al., 1989). These studies support the conclusion that lindane is
not estrogenic and may have some anti-estrogenic action. While
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these anti-estrogenic effects are not desirable, there is no
evidence that they would pose an increased risk for breast cancer.
Lindane ranks among the ten least used pesticides in the U.S.
during the early 1990s. It is a RUP. The potential for exposure
for the general population to this chemical is thus relatively
low.
VIII. Identification of Research Gaps, and Other
Recommendations
· Large epidemiological studies are needed on cancer
incidences in populations previously exposed to lindane,
especially women who may have been exposed
occupationally.
· Studies need to evaluate breast cancer incidences in
populations that were exposed as children to head lice
treatments containing lindane.
· More animal bioassays that meet current guidelines are
needed to confirm the association of lindane with hepatic
carcinomas in mice and thyroid tumors in female rats. The
incidence of mammary tumors should be evaluated in these
studies.
· A new estrogen receptor (beta-ER) has been identified and
cloned recently (Kuiper et al., 1996). It should be
determined if lindane interacts with this estrogen receptor.
· While some mechanisms for tumor promotion by lindane
have been suggested, the tumor promoting response to
lindane has not been adequately addressed in animals.
Lindane needs to be tested for tumor promotion with
known mammary carcinogens.
IX. Summary of New Human Studies Currently
Being Conducted
We have pointed out the need for more epidemiological studies
on cancer rates and endocrine disruption-effects from exposure to
lindane. Several ongoing / proposed studies on lindaneÕs effects
were found in the CRISP Database (see Appendix A) and are
outlined below.
Studies of Occupational Cancer--Pesticides:
(Alavanja, M., Blair, A., NCI, NIH, extracted from the
CRISP Database, FY 97, and Personal Communication)
A large scale ÒAgricultural Health StudyÓ proposes to look at
the relationship between agricultural exposures and cancer risk.
Enrollment in this study includes 90,000 men and women
farmers, pesticide applicators and farmerÕs wives from Iowa and
North Carolina. Besides conducting interviews to determine
pesticide use, it will also seek information on lifestyle factors,
medical and family history of disease and diet.
Cellular Mechanisms of Endocrine Disruptors:
(Adler, SR, Washington University, St. Louis, extracted
from the CRISP Data base, FY 98)
One study that was recently funded by the National Institutes of
Health (NIH) () will evaluate health effects from lindane exposure
in women. The study proposes to examine a panel of chemicals,
including lindane, to determine their estrogenic potential and
their effect on womenÕs health and the health of future offspring.
The chemicals will be evaluated for their potential to bind the
ER and affect gene regulation. These effects will be confirmed in
ER Òknock-outÓ mice.
Lindane Modification of Uterine Muscle:
(Loch-Caruso, R., University of Michigan, Ann Arbor,
extracted from the CRISP Database, FY 97)
The hypothesis of this proposal is that lindane inhibition of gap
junctional communication relaxes uterine muscle and interferes
with parturition. The author proposes to study lindaneÕs effects
on parturition in rats, and conduct in vitro experiments to
evaluate the mechanisms by which lindane affects uterine
contractility and gap junctional communication. Identification of
the mechanism by which lindane affects gap junctional
communication and uterine contractility would lead to an
understanding of its toxic effects on the reproductive system and
other tissues.
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XI. Appendix A. Common Abbreviations, Acronyms and Symbols
AFB1 aflatoxin B1
BCERF Program on Breast Cancer and Environmental 
Risk Factors in New York State, based the 
Cornell Center for the Environment, 
Institute of Comparative and Environmental 
Toxicology
beta-PCCH beta-pentachlorocyclohex-1-ene
BHC benzene hexachloride
bwt body weight
CAS Chemical Abstract Service
CfE Cornell Center for the 
Environment
CI Confidence Interval
Cl chlorine
CRISP Computer Retrieval of Information on 
Scientific Projects; database of scientific intra 
and extramural projects supported by the 
Dept. of Health and Human Services (i.e., 
NIH, EPA, USDA)
DEN diethylnitrosamine; a carcinogen in the liver
DMBA 7,12-dimethylbenz[a]anthracene; known 
mammary carcinogen
DNA deoxyribonucleic acid
EB estradiol benzoate
EPA Environmental Protection Agency
ER estrogen receptor
E-SCREEN screening assay for estrogenicity that measures
proliferative response in estrogen-dependent 
breast tumor cells
FDA Food and Drug Administration
FSH follicle stimulating hormone
GGT g-glutamyltranspeptidase
HA The health advisories are non-enforceable limits
of the concentration of the chemical in the 
drinking water that is not expected to cause any
adverse noncarcinogenic health effects when 
consumed for no more than the time period 
specified, with a margin of safety
HCB hexachlorobenzene
HCH Hexachlorocyclohexane
IARC International Agency for Research on Cancer, 
headquartered in Lyon, France
ICET Institute for Comparative and Environmental 
Toxicology
i.p. interperitoneal
IRIS Integrated Risk Information System; Database 
maintained by EPA available through the 
National Library of Medicine MEDLARS 
system.
kg kilogram
L liter
LH luteinizing hormone
LI Long Island, New York
mg microgram
m3 cubic meter
mg milligram
MCF-7 Michigan Cancer Foundation; cells derived 
from human breast tumor
MCL Maximum Contaminant Level; enforceable 
limit set by EPA which sets the maximum 
level of a contaminate in a public drinking 
water supply
mM micromolar
mM millimolar
n number of subjects/animals in the group
NHL non-HodgkinÕs lymphoma
NIOSH National Institute of Occupational Safety and 
Health
NCI National Cancer Institute
NIEHS National Institute of Environmental Health 
and Safety
NIH National Institutes of Health
NM nasal mucosal cells
NMU N-nitroso-N-methyurea; mammary carcinogen
NTIS National Technical Information Service; 
repository for federal agency technical reports
NTP National Toxicology Program
NY New York
NYS New York State
OR Odds Ratio
OSHA Occupational Safety and Health 
Administration
PCBs polychlorinated biphenyls
PDR PhysicianÕs Desk Reference
PKC protein kinase C
PMN polymorphonuclear neutrophils
PMR Proportional Mortality Ratio; PMR = number
of deaths in the cohort compared to the 
expected number of deaths in the general 
population
p.o. per oral
ppm parts per million
ppb parts per billion
ppt parts per trillion
RR Relative Risk
RfD Reference Dose
RPAR Rebuttable Presumption Against Registration
RUP Restricted Use Pesticide
SCE sister chromatid exchange
SRBC sheep red blood cells
SSB single stranded breaks
SD Standard Deviation
SMR Standardized Mortality Ratio; SMR= the ratio
of ÒobservedÓ to ÒexpectedÓ deaths
TPA 12-O-tetradecanoylphobol-13-acetate
TSH thyroid stimulating hormone
U.S. United States
USDA United States Department of Agriculture
USEPA United States Environmental Protection 
Agency
UV ultraviolet light
WHO World Health Organization
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Symbols:
a alpha
b beta
g gamma
< less than
> greater than
% percent
p p value
+  plus or minus
= equal
¨ registered trademark
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XII Appendix B. Critical Evaluations of Breast Cancer Carcinogenicity
This includes an overview of the Critical Evaluations and explanation of the BCERF Breast Carcinogenicity Classification Scheme
The Process
Starting Point - Existing Critical Evaluations on Evidence of Carcinogenicity
IARC Monographs (International Agency for Research on Cancer)
NTP ARC (National Toxicology Program, Annual Report on Carcinogens)
ATSDR (Agency for Toxic Substances and Disease Registry)
Conduct Literature Searches using databases to obtain historical and the most recent information; i.e. Toxline, Medline, Biosis,
Cancerlit
· Peer-reviewed scientific literature-available through Cornell libraries and interlibrary loans.
· Technical Reports-NTIS-National Technical Information Service
· TOXNET databases--EPAÕs IRIS database source of oncogenicity and regulatory status information
· Grey literature--Studies submitted to EPA that are not published:
-Industry generated oncogenicity studies
-Some abstracts (short summaries) are on line (IRIS database)
-Request reports from industry
-Request reports from EPA through Freedom of Information Act
The critical evaluation will include some general background information, including chemical name, CAS#, trade name, history of
use, and current regulatory status.
Evidence of cancer in other (non-breast) organ systems will be provided in synopsis form with some critical commentary, along with
the current overall carcinogenicity classification by international (IARC) and U.S. Federal Agencies (NTP, EPA).
Human epidemiological studies, animal studies, and other relevant studies on possible mechanisms of carcinogenesis will be critically
evaluated for evidence of exposure to agent and breast cancer risk based on Òstrength of evidenceÓ approach, according to a
modification of IARC criteria as listed in the IARC Preamble.  (See below for a more detailed explanation of the BCERF
Carcinogenicity classification scheme)
The emphasis of the document will be on critical evaluation of the evidence for breast cancer carcinogenicity, classification of the
agentÕs breast cancer risk, identification of research gaps, and recommendations for future studies.  A section will also be devoted to
brief summaries of new research studies that are in progress.  A bibliography with all cited literature is included in each critical
evaluation.  Major international, federal and state agencies will be provided with copies of our report.
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General Outline of BCERF Critical Evaluations
I. Chemical Information
A. Common Name
B. Chemical Name(s)
C. Chemical Formula(s)
D. Trade Name(s)
E. CAS # (Chemical Abstract Subject Number)
F. Chemical Structure
II. History of Use
1. Date of first registration
2. Uses
3. Past Usage / If available, current usage levels in US and NYS
III. Current Regulatory Status
A. Current Regulatory Status, EPA
B. Other sections as applicable
IV. Summary on Evidence of Overall Carcinogenicity (Non-Breast Sites)
A. Human Studies
B. Animal Studies
C. Current Classification of Carcinogenicity by other Agencies
1. IARC (International Agency for Research on Cancer)
2. NTP (National Toxicology Program)
3. EPA (Environmental Protection Agency)
V.  Critical Evaluation of the Scientific Evidence for Breast Carcinogenicity
A. Humans Studies will include:
1. Case-Studies
2. Human Epidemiological Cohort Studies
3. Human Epidemiological Case-Control Studies
B. Experimental Animal Studies
C. Other Relevant Information, including mechanisms by which exposure may affect breast cancer risk (examples: co-
carcinogenicity, estrogenicity, endocrine disruptor, mutagenicity, tumor promotion, cell proliferation, oncogene/tumor
suppressor gene expression, immune function, etc.)
VI.  Other Relevant Information
A. Specific for the pesticide; (i.e. may include information on environmental fate)
B. When available will summarize information on detection /accumulation in human tissues / and validation of biomarkers
VII.  Summary, Conclusions, Recommendation for Classification
VIII. Identification of Research Gaps, and Other Recommendations
IX.   Brief Summaries of New Human Studies Currently Being Conducted
X.    Bibliography
XI.   Appendix A. Common Abbreviations, Acronyms and Symbols
XII.  Appendix B. Critical Evaluations of Breast Carcinogenicity
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BCERF Breast Carcinogenicity Classification Scheme
(adapted from the IARC Preamble by S.M.Snedeker)
Group 1:  Human breast carcinogen; sufficient evidence of
carcinogenicity to humans is necessary.  Sufficient evidence is
considered to be evidence that a causal relationship has been
established between exposure to the agent and human breast
cancer.
Group 2A:  Probable breast carcinogen; this category
generally includes agents for which there is 1) limited evidence
of breast carcinogenicity in humans   and   sufficient evidence  of
mammary carcinogenicity in experimental animals.  The
classification may also be used when there is 2) limited evidence
of breast carcinogenicity in humans and strong supporting
evidence from other relevant data, or when there is 3) sufficient
evidence  of mammary carcinogenicity in experimental animals
and strong supporting evidence from other relevant data.
Group 2B:  Possible breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  in humans
in the absence of sufficient evidence  in experimental animals; 2)
inadequate evidence  of carcinogenicity in humans or when
human data is nonexistent but there is sufficient evidence  of
carcinogenicity in experimental animals, 3) inadequate evidence
or no data in humans but with limited evidence  of
carcinogenicity in experimental animals together with
supporting evidence from other relevant data.
Group 2C:  Potential to affect breast cancer risk; this
category includes agents for which there is inadequate or
nonexistent human and animal data, but there is
supporting evidence from other relevant data that identifies a
mechanism by which the agent may affect breast cancer risk.
Examples are, but are not limited to:  evidence of agentÕs
estrogenicity, disruption of estrogen metabolism resulting in
potential to affect exposure to estrogen; evidence of breast  tumor
promotion, progression or co-carcinogenicity; increased
expression of proto-oncogenes or oncogenes; evidence of
inactivation of tumor suppressor gene associated with breast
cancer; evidence of adverse effect on immune function; or
evidence of a structural similarity to a known breast carcinogen
(structure-activity relationship).
Group 3: Not classifiable as to its breast carcinogenicity to
humans.  Agents are placed in this category when they do not
fall into any other group.
Group 4: Probably not a breast carcinogen in humans:
This category is used for agents for which there is evidence
suggesting a lack of breast carcinogenicity in human studies and
in animal studies, together with a lack of related evidence which
may predict breast cancer risk. The absence of studies does not
constitute evidence for a lack of breast carcinogenicity.
Brief Definitions of Sufficient, Limited, and Inadequate
Evidence:
(adapted for breast carcinogenicity from the IARC Preamble by
S.M. Snedeker)
Human Studies
Sufficient evidence of carcinogenicity in humans:  Must
have established evidence   between    exposure   to   the    agent    and
human   breast   cancer .  Case-reports are given the least weight in
considering carcinogenicity data in humans--they are suggestive
of a relationship, but by themselves cannot demonstrate
causality. Consistent, case-control studies which have controlled
for confounding factors and have found high relative risks of
developing breast cancer in relation to an identified exposure are
given the most weight in determining a causal relationship.
Limited evidence of breast carcinogenicity in humans:  A
positive association has been observed between exposure to the
agent and breast cancer, but chance, bias or confounding factors
could not be ruled out.
Inadequate evidence of breast carcinogenicity in humans:
The available studies are of insufficient quality, consistency or
statistical power to permit a conclusion regarding the presence
or absence of a causal association.
Experimental Animal Studies
Sufficient evidence of breast carcinogenicity in animals:
Evidence of malignant tumors or combination of benign and
malignant tumors in (a) two or more species of animals, (b) or
two or more independent studies in one species carried out at
different times or in different laboratories or under different
protocols.
Limited evidence of breast carcinogenicity in animals: The
studies suggest a carcinogenic effect, but are limited for making
a definitive evaluation because: (a) the evidence of
carcinogenicity is restricted to a single experiment; (b) there are
unresolved questions regarding the adequacy of the design,
conduct or interpretation of the study; or (c) the agent increases
the incidence of only benign neoplasms of lesions of uncertain
neoplastic potential, or of certain neoplasms which may occur
spontaneously in high incidences in certain strains of animals.
Inadequate evidence of breast carcinogenicity in animals:
The studies cannot be interpreted as showing either the presence
or absence of a carcinogenic effect because of major qualitative or
quantitative limitations.
